Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
Latest Video
New Stories
-
Pfizer officially makes Sydney CBD its new home
December 10, 2018 - - Latest News -
AbbVie's Kirsten O'Doherty: Judge people on output, not attendance
December 10, 2018 - - Latest News -
The facts on workplace flexibility
December 10, 2018 - - Latest News -
Greg Hunt welcomes 'collaboration' on flu vaccine
December 10, 2018 - - Latest News -
Who understands and will pay for the 'combined view'?
December 10, 2018 - - Latest News -
Hurdles mount for supply chain payment reform
December 7, 2018 - - Latest News -
Get ready for 2019 'Pharma 2 Peak Kosi Challenge'
December 7, 2018 - - Latest News